• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DarioHealth Corp. filed SEC Form 8-K: Leadership Update

    7/10/26 5:10:06 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email
    false 0001533998 0001533998 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of Earliest Event Reported): July 10, 2026

     

    DARIOHEALTH CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware  001-37704  45-2973162
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    322 W 57th St., #33B
    New York, New York 10019 (Address of Principal Executive Offices)

     

    972- 4-770-6377

    (Issuer’s telephone number)

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which 
    registered
    Common Stock, par value $0.0001 per share   DRIO   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Commercial Officer of DarioHealth Corp., or the Company, was extended for an indefinite period. During Mr. Nelson’s leave of absence, his responsibilities are being assumed by members of the Company’s senior management team.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: July 10, 2026 DARIOHEALTH CORP.
       
      By: /s/ Chen Franco-Yehuda
      Name:  Chen Franco-Yehuda
      Title: Chief Financial Officer, Treasurer and Secretary

     

     

     

    Get the next $DRIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Palumbo John R

    3 - DarioHealth Corp. (0001533998) (Issuer)

    4/13/26 4:05:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform

    Contract award for over 100,000 eligible employees marks Dario's fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition managementProgram expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027NEW YORK, July 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/o

    7/16/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%

    DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for DarioDario IQ's AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data pointsNEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-

    7/13/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership

    Agreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk and total cost of care via payer relationships NEW YORK, July 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell.  This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, repre

    7/6/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    SEC Filings

    View All

    DarioHealth Corp. filed SEC Form 8-K: Leadership Update

    8-K - DarioHealth Corp. (0001533998) (Filer)

    7/10/26 5:10:06 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DarioHealth Corp.

    10-Q - DarioHealth Corp. (0001533998) (Filer)

    5/13/26 6:05:57 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by DarioHealth Corp.

    SD - DarioHealth Corp. (0001533998) (Filer)

    5/7/26 4:05:07 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships

    O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to careO'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transitionNEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic

    6/30/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

    Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.  The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye

    4/13/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports First Quarter 2026 Financial and Operating Results

    First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growthOperating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarterOperating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarterChannel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered livesNow in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks

    5/13/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

    Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 13th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Wednesday, May13th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-80

    5/4/26 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care